• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    FDA Approval for ZYNLONTA issued to ADC Therapeutics SA

    4/23/21 1:46:03 PM ET
    $ADCT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ADCT alert in real time by email
    Biologic License Application (BLA): 761196
    Company: ADC Therapeutics SA
    • Email

    Products on BLA 761196

    Drug Name Active Ingredients Strength Dosage Form/Route Marketing Status TE Code RLD RS
    ZYNLONTA LONCASTUXIMAB TESIRINE-LPYL 10MG INJECTABLE;INJECTION Prescription None No No

    Approval Date(s) and History, Letters, Labels, Reviews for BLA 761196

    Original Approvals or Tentative Approvals
    Action Date Submission Action Type Submission Classification Review Priority; Orphan Status Letters, Reviews, Labels, Patient Package Insert Notes Url
    04/23/2021 ORIG-1 Approval N/A Label (PDF)
    https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761196s000lbl.pdf

    Labels for BLA 761196

    Action Date Submission Supplement Categories or Approval Type Letters, Reviews, Labels,
    Patient Package Insert
    Note Url
    04/23/2021 ORIG-1 Approval Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761196s000lbl.pdf
    Get the next $ADCT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ADCT

    DatePrice TargetRatingAnalyst
    11/8/2024$6.00Overweight
    Stephens
    5/30/2024Overweight
    Cantor Fitzgerald
    3/28/2024$11.00Buy
    Guggenheim
    8/10/2023Underweight → Neutral
    JP Morgan
    4/24/2023$7.00 → $2.00Neutral → Underperform
    BofA Securities
    12/6/2022$12.00Overweight
    CapitalOne
    11/9/2022$14.00 → $7.00Buy → Neutral
    BofA Securities
    9/21/2022$5.00Overweight
    JP Morgan
    More analyst ratings